If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRuffer Investment Company Regulatory News (RICA)

Share Price Information for Ruffer Investment Company (RICA)

Share Price is delayed by 15 minutes
Get Live Data
291.00    -1.50 (-0.51%)
Bid:
291.00
Ask:
294.00
Spread: 3.00 (1.031%)
Market Cap: £858.34m
RICA Live PriceLast checked at - London Stock Exchange

Intraday Ruffer Investment Company Share Chart

Interim Financial Report

18 Mar 2026 07:00

RNS Number : 0385X
Ruffer Investment Company Limited
18 March 2026
 

18 March 2026

 

RUFFER INVESTMENT COMPANY LIMITED

(a closed-ended investment company incorporated in Guernsey with registration number 41996)

(the "Company")

 

Interim Financial Report

The Company has today, in accordance with DTR 6.3.5, released its Interim Financial Report for the six months ended 31 December 2025 and a copy is attached.

http://www.rns-pdf.londonstockexchange.com/rns/0385X_1-2026-3-17.pdf

The Interim Financial Report is also available via the Investment Manager's website at www.ruffer.co.uk/2025-ric-interim-report.

A copy of the Interim Report has been submitted to the National Storage Mechanism and will shortly be available at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

Summary

NAV TR over the six months to 31 December 2025 was 4.9%.

The discount of the share price to NAV marginally widened to 3.6% at 31 December 2025 (from 3.4% at 30 June 2025), resulting in a slightly lower Share Price TR of 4.7% over the same period.

The NAV TR and Share Price TR for the twelve months to 31 December 2025 were 10.9% and 12.1% respectively.

The Company's investment performance has therefore met the Company's aim to generate consistent positive returns, however financial markets are performing. Additionally, returns over six and 12 months exceeded the Company's objective of twice the Bank of England base rate.

The Company has declared an interim dividend of 2.85p for the six months to 31 December 2025 (2.85p in 2024/2025).

A key action was the continuation of the Company's significant share buyback programme, which saw 2.2% of the shares outstanding at the end of the last financial year repurchased over the six-month period. Since the first share repurchase in August 2023, the Company has bought back 23.0% of its issued share capital, including 9.8% in the 2025 calendar year. The buyback is a continuing benefit for shareholders, enhancing NAV per share by 0.5% in 2025.

Financial Highlights

31 Dec 25

30 Jun 25

Share price

294.00p

284.00p

NAV as calculated on an IFRS basis1

£900.61m

£888.20m

NAV as reported to the LSE

£900.29m

£891.59m

Market capitalisation

£868.50m

£858.18m

Number of shares in issue

295,407,050

302,177,764

NAV per share as calculated on an IFRS basis1

304.87p

293.93p

NAV per share as reported to the LSE

304.76p

295.06p

 

Key Performance Indicators

31 Dec 25 %

31 Dec 24 %

Share price total return over six months

4.7

0.2

NAV total return per share over six months1,2

4.9

(0.4)

Discount of traded share price to NAV1

(3.6)

(4.5)

Dividend per share over six months3

3.35p

3.10p

Annualised dividend yield4

2.3

2.3

Annualised NAV total return per share since launch2

6.9

6.7

Ongoing charges ratio

1.08

1.08

1 This is the NAV/NAV per share (on an IFRS basis) as per the Company's Financial Statements for the six months ended 31 December 2025.

2 Assumes reinvestment of dividends.

3 Dividend declared during the period.

4 Annualised dividend yield is calculated using share price at the period end and dividends declared during the period.

Investment Performance and Outlook

RICL's positive performance in the six months to 31 December 2025 exemplifies Ruffer's ability to deliver positive returns in benign markets whilst maintaining protection to preserve capital in the event of volatility. The principal contributors to returns in the period were gold and precious metals exposure (+4.0%) and global equities (+3.5%), more than offsetting the continuing cost of protection strategies including credit and derivatives (-2.4%) and the yen (-0.9%).

The Investment Manager's report (as of 31 December 2025, and as announced by the Company by way of RNS on 27 January 2026)) highlights that the structural shifts examined in the Company's last full-year report have become realities shaping markets today. The disinflationary era underpinned by globalisation and geopolitical stability, alongside cheap labour, energy and capital, continues to unwind. Fragmentation has accelerated, with the US and China now openly competing to carve out spheres of influence and to control critical technologies and resources. Recent events are a timely reminder that this fragmentation is happening in front of investors' eyes and can flare into real-world disruption at any time.

Against this backdrop, the portfolio is positioned to reflect a variety of potential market outcomes, in line with the Company's all-weather approach. It maintains its defensive spine, made up of credit and derivative strategies, the yen and dry powder in the form of short-dated bonds and cash. At the same time, the Investment Manager has looked to reinforce the Company's exposure to attractively priced growth opportunities should risk appetite be sustained. In combination, this should allow the portfolio to prosper regardless of whether 2026 brings another year of steady ascent, a moment of overheating or renewed weakness.

The Board carefully evaluates the performance of the Investment Manager over various time periods. Ruffer's performance has now exceeded the Company's objective over one year, 10 years and 20 years. Recent performance is therefore steadily clawing back the weaker three- and five-year figures. Over the entire 21 years since inception to 31 December 2025, the Company has delivered an annualised NAV TR per share of 6.9%, exceeding the objective of twice the Bank of England base rate, which was 4.0% for the period.

The Company owns diverse growth assets, predominantly outside the US, for a scenario of benign reflation or resurgent inflation. It also retains significant protection against a sell-off if there were to be a growth slowdown or deflation. Current geopolitical tension or their resolution could impact the fragile balance between these outcomes. Consequently, the Board remains confident that RICL has an important role to play in investors' portfolios during these uncertain times.

 

Enquiries:

 

Apex Fund and Corporate Services (Guernsey) Limited

Company Secretary

James Taylor

DDI: +44 (0) 20 3530 3600

Email: RufferCoSec@apexgroup.com

 

 

LEI 21380068AHZKY7MKNO47

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR FFFEFVSIDLIR
Date   Source Headline
17th May 20232:49 pmRNSNet Asset Value(s)
11th May 20234:46 pmRNSIssue of Equity & Total Voting Rights
10th May 202312:19 pmRNSNet Asset Value(s)
3rd May 20234:38 pmRNSIssue of Equity & Total Voting Rights
3rd May 202312:19 pmRNSNet Asset Value(s)
2nd May 202312:51 pmRNSNet Asset Value(s)
28th Apr 20233:50 pmRNSTotal Voting Rights
27th Apr 20234:42 pmRNSIssue of Equity and Total Voting Rights
26th Apr 20232:49 pmRNSNet Asset Value(s)
19th Apr 20234:57 pmRNSIssue of Equity and Total Voting Rights
19th Apr 20233:38 pmRNSNet Asset Value(s)
18th Apr 202312:00 pmRNSMonthly Investment Report - March 2023
13th Apr 20233:49 pmRNSIssue of Equity and Total Voting Rights
12th Apr 20232:58 pmRNSNet Asset Value(s)
6th Apr 20233:58 pmRNSIssue of Equity and Total Voting Rights
5th Apr 20231:58 pmRNSNet Asset Value(s)
3rd Apr 20233:11 pmRNSNet Asset Value(s)
31st Mar 20233:54 pmRNSTotal Voting Rights
30th Mar 20235:12 pmRNSIssue of Equity and Total Voting Rights
29th Mar 20233:01 pmRNSNet Asset Value(s)
24th Mar 20235:23 pmRNSBlock listing Interim Review
23rd Mar 20234:38 pmRNSIssue of Equity and Total Voting Rights
22nd Mar 20235:10 pmRNSIssue of Equity and Total Voting Rights
22nd Mar 20233:13 pmRNSNet Asset Value(s)
22nd Mar 202311:37 amRNSDirector Declaration
16th Mar 20235:16 pmRNSIssue of Equity and Total Voting Rights
15th Mar 20235:53 pmRNSIssue of Equity and Total Voting Rights
15th Mar 20233:43 pmRNSNet Asset Value(s)
13th Mar 20237:00 amRNSBlock listing Interim Review
9th Mar 20237:00 amRNSMonthly Investment Report - February 2023
8th Mar 20233:03 pmRNSNet Asset Value(s)
2nd Mar 20233:38 pmRNSIssue of Equity and Total Voting Rights
1st Mar 20232:52 pmRNSNet Asset Value(s)
28th Feb 20237:00 amRNSTotal Voting Rights
23rd Feb 20233:41 pmRNSIssue of Equity and Total Voting Rights
22nd Feb 20233:42 pmRNSNet Asset Value(s)
22nd Feb 20237:01 amRNSDividend Declaration
22nd Feb 20237:00 amRNSHalf-year Report
16th Feb 20234:44 pmRNSIssue of Equity and Total Voting Rights
15th Feb 20234:31 pmRNSIssue of Equity and Total Voting Rights
15th Feb 20233:08 pmRNSNet Asset Value(s)
13th Feb 20239:00 amRNSChange of Registered Office
10th Feb 20237:00 amRNSMonthly Investment Report - January 2023
8th Feb 202312:53 pmRNSNet Asset Value(s)
2nd Feb 20235:44 pmRNSIssue of Equity and Total Voting Rights
1st Feb 202312:14 pmRNSNet Asset Value(s)
31st Jan 20234:00 pmRNSTotal Voting Rights
26th Jan 20234:45 pmRNSIssue of Equity & Total Voting Rights
25th Jan 202312:29 pmRNSNet Asset Value(s)
19th Jan 20234:33 pmRNSIssue of Equity and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.